

## **Calliditas Therapeutics' nomination committee for the AGM 2019**

**Calliditas Therapeutics AB (publ.) publishes the nomination committee's composition for the AGM in 2019.**

The nomination committee, which is appointed in accordance with the principles adopted by the extraordinary general meeting on September 14, 2017, consists of:

- Nina Rawal, appointed by Stiftelsen Industrifonden
- Jon Öyvind Eriksen, appointed by Investinor AS
- Karl Tobieson, appointed by Linc AB
- Thomas Eklund (chairman of the board of directors)

The nomination committee shall, before the annual general meeting 2019, prepare a proposal for the election of chairman and other members of the board of directors, the election of chairman of the annual meeting, election of auditors, the determination of fees and matters pertaining thereto.

For more information please visit:

<https://www.calliditas.se/en/nomination-committee-2314/>

Shareholders who wish to submit proposals to the nomination committee for the annual general meeting on May 8, 2019 can do so by e-mail to [info@calliditas.com](mailto:info@calliditas.com). Proposals should be submitted to the nomination committee before March 19, 2019.

### **For further information, please contact:**

Fredrik Johansson, CFO at Calliditas

Email: [fredrik.johansson@calliditas.com](mailto:fredrik.johansson@calliditas.com)

Telephone: +46 703 52 91 90

*The information was submitted for publication, through the agency of the contact person set out above, at 10:00 CEST on October 4, 2018.*

### **About Calliditas Therapeutics**

Calliditas Therapeutics is a specialty pharmaceutical company based in Stockholm, Sweden, focused on developing high quality pharmaceutical products for patients with a significant unmet medical need in niche indications, in which the Company can partially or completely participate in the commercialization efforts. The Company is focused on the development and commercialization of the product candidate Nefecon, a unique formulation optimized to combine a time lag effect with a concentrated release of the active substance budesonide, within a designated target area. This patented, locally acting formulation is intended for treatment of patients with the inflammatory renal disease IgA nephropathy. Calliditas Therapeutics aims to take Nefecon through a global Phase 3 study to commercialization. Visit [www.calliditas.com](http://www.calliditas.com) for further information.